Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose high- vs low-dose versus oral iron in iron deficiency anemia with non-dialysis-dependent chronic kidney disease
NL-OMON39180Phase 3Active, not recruiting
- Sponsor
- CSL Vifor
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose and ferrous sulfate in iron deficiency anemia (IDA) (3 arms), sponsored by CSL Vifor. Primary endpoint: Time to initiation of other anaemia management. Started Jun 2011; status: active, not recruiting.
02
Drugs
ferric carboxymaltoseferrous sulfate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON39180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39180.